Loading...

PLSE PULSE BIOSCIENCES INC US FDA Inspections 8-K Filing

PLS

PLS

PULSE BIOSCIENCES INC

(PLSE)

2026 8-K

Stock Sale Agreement

Q1 2026 Results

Key Clinical Findings

Investor Presentation Update

Leadership Change

Clinical Study Launch

Director Compensation Update

Organizational Realignment

Clinical Study Enrollment

Clinical Study Results

Investor Update

Management Change

Financial Update

Equity Agreement Signed

Study Data Released

Investor Update

New Board Member

FDA Approval Announcement

Annual Meeting Results

Research Collaboration

Investor Update

Financial Update

First Patient Enrolled

nPulse™ Results

Shareholder Meeting Results

FDA Approval Announcement

First Patient Enrolled

Clinical Study Results

Financial Statements

Financial Results

CFO Appointment

Investor Update

CEO Appointment

Warrant Redemption

CEO Resignation

Stock Purchase Plan

Positive Study Results

Quarterly Results

Investor Update

Equity Distribution Agreement

FDA Breakthrough Device Des...

Rights Offering

Annual Meeting and Voting R...

Rights Offering

Rights Offering

Financial Results Announcement

Rights Offering

Financial Results and Right...

FDA Clearance Announcement

Investor Presentation

Stockholder Meeting

Programmatic Updates

Earnings Reports

Bonuses Approved

Earnings Reports

Public Disclosure

Departure of Directors

Financial Results Announcement

Redemption of Warrants

Private Placement

Compensation Changes

Private Placement Agreement

Financial Results and Manag...

Loan Agreement Amendment

External Links:

On April 7, 2026, Pulse Biosciences, Inc. announced the first enrollment of patients in its NANOPULSE-AF clinical study for treating drug-resistant atrial fibrillation, with 215 participants planned across multiple sites. The first seven patients were treated at St. Bernards Medical Center in Arkansas.

AI Assistant

PULSE BIOSCIENCES INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.